

## Sélection des publications 2019

- Auvray M, Tougeron D, Auclin E, Moulin V, Artru P, Hautefeuille V, Hammel P, Lecomte T, Locher C, Sickersen G, Coriat R, Lecaille C, Vernerey D, Taieb J, Pernot S.  
*Efficacy and Safety of Aflibercept in Combination With Chemotherapy Beyond Second-Line Therapy in Metastatic Colorectal Carcinoma Patients: An AGEO Multicenter Study.*  
Clin Colorectal Cancer. 2019 Sep 4. pii: S1533-0028(19)30090-8. doi: 10.1016/j.clcc.2019.08.003. [Epub ahead of print]
- Bagacean C, Tempescul A, Ternant D, Banet A, Douet-Guilbert N, Bordron A, Bendaoud B, Saad H, Zdrengeha M, Berthou C, Paintaud G, Renaudineau Y.  
*17p deletion strongly influences rituximab elimination in chronic lymphocytic leukemia.*  
J Immunother Cancer. 2019, 7 : 22
- Bauvois A, Larivière M, Watier H, Maillot F.  
*[Monoclonal Antibodies for Monogenic Diseases: A 2019 Update]*  
Med Sci (Paris). 2019, 35 : 1026-1028
- Beck A, Dumontet C, Joubert N.  
*[Antibody-drug conjugates in oncology. New strategies in development].*  
Med Sci (Paris). 2019, 35 : 1043-1053
- Beck A, Dumontet C, Joubert N.  
*[Antibody-drug conjugates in oncology. Recent success of an ancient concept].*  
Med Sci (Paris). 2019, 35 : 1034-104
- Bejan-Angoulvant T, Alexandre J.  
*[Mechanism of Action and Adverse Effects of Monoclonal Antibodies]*  
Med Sci (Paris). 2019, 35 : 1114-1120
- Bequignon E, Dhommée C, Angely C, Thomas L, Bottier M, Escudier E, Isabey D, Coste A, Louis B, Papon JF, Gouilleux-Gruart V  
*FcRn-Dependent Transcytosis of Monoclonal Antibody in Human Nasal Epithelial Cells In Vitro: A Prerequisite for a New Delivery Route for Therapy?*  
Int J Mol Sci. 2019 Mar 19;20(6). pii: E1379
- Bensalem A, Mulleman D, Thibault G, Azzopardi N, Goupille P, Paintaud G, Ternant D.  
*CD4+ count-dependent concentration-effect relationship of rituximab in rheumatoid arthritis.*  
Br J Clin Pharmacol. 2019 Aug 27. doi: 10.1111/bcp.14102. [Epub ahead of print]
- Bensalem A, Mulleman D, Paintaud G, Azzopardi N, Gouilleux-Gruart V, Cornec D, Specks U, Ternant D.  
*Non-Linear Rituximab Pharmacokinetics and Complex Relationship between Rituximab Concentrations and Anti-Neutrophil Cytoplasmic Antibodies (ANCA) in ANCA-Associated Vasculitis: The RAVE Trial Revisited.*  
Clin Pharmacokinet. 2019, 85 : 2747-2758
- Boutin JA, Bouillaud F, Janda E, Gacsalyi I, Guillaumet G, Hirsch EC, Kane DA, Nepveu F, Reybier K, Dupuis P, Bertrand M, Chhour M, Le Diguarher T, Antoine M, Brebner K, Da Costa H, Ducrot P, Giganti A, Goswami V, Guedouari H, Michel PP, Patel A, Paysant J, Stojko J, Viaud-Massuard MC, Ferry G.  
*S29434, a Quinone Reductase 2 Inhibitor: Main Biochemical and Cellular Characterization.*  
Mol Pharmacol. 2019, 95 : 269-285
- Brachet-Botineau M, Deynoux M, Vallet N, Polomski M, Juen L, Hérault O, Mazurier F, Viaud-Massuard MC, Prié G, Gouilleux F.  
*A Novel Inhibitor of STAT5 Signaling Overcomes Chemotherapy Resistance in Myeloid Leukemia Cells.*

- Chabi S, Uzan B, Naguibneva I, Rucci J, Fahy L, Calvo J, Arcangeli ML, Mazurier F, Pflumio F, Haddad R. *Hypoxia Regulates Lymphoid Development of Human Hematopoietic Progenitors*. Cell Rep. 2019, 29 : 2307-2320.e6.
- Charton E, Bachet JB, Hammel P, Desramé J, Chibaudel B, Cohen R, Debourdeau P, Dauba J, Lecomte T, Seitz JF, Tournigand C, Aparicio T, Guerin-Meyer V, Taieb J, Volet J, Louvet C, Anota A, Bonnetain F. *Impact on health-related quality of life deterioration-free survival of a first-line therapy combining nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil for patients with metastatic pancreatic cancer: Results of the randomized phase II AFUGEM GERCOR clinical trial*. Cancer Med. 2019,8 : 5079-5088
- Chautard R, Ibrahim S, Gueguinou M, Lecomte T, Raoul W. *Micro-ARN et cancer colorectal*. HGOD. 2019. doi : 10.1684/hpg.2019.1896
- Deveuve Q, Gouilleux-Gruart V, Thibault G, Lajoie L. *[The hinge region of therapeutic antibodies: major importance of a short sequence]*. Med Sci (Paris). 2019, 35 : 1098-1105
- Dujardin PA, Léger J, Lecomte T, Patat F, Chassagnon G, Bleuzen A. *Perfusion Quantification of Liver Metastases of Colorectal Cancer Treated with Anti-angiogenic-Based Therapy: Assessment of Intra- and Inter-observer Reproducibility of Parameters in Three Regions of Interest Outlining Lesions*. Ultrasound Med Biol. 2019, 46 : 286-296
- Dumet C, Pottier J, Gouilleux-Gruart V, Watier H. *Insights into the IgG heavy chain engineering patent landscape as applied to IgG4 antibody development*. MAbs. 2019, 11 : 1341-1350
- Dumet C, Watier H. *[Which Immunoglobulin Heavy Chains for Which Immunostimulatory Antibodies?]* Med Sci (Paris). 2019, 35 : 975-981
- Ghesquieres H, Chevrier M, Laadhari M, Chinot O, Choquet S, Moluçon-Chabrot C, Beauchesne P, Gressin R, Morschhauser F, Schmitt A, Gyan E, Hoang-Xuan K, Nicolas-Virelizier E, Cassoux N, Touitou V, Le Garff-Tavernier M, Savignoni A, Turbiez I, Soumelis V, Houillier C, Soussain C. *Lenalidomide in Combination with Intravenous Rituximab (REVRI) in Relapsed/Refractory Primary CNS Lymphoma or Primary Intraocular Lymphoma: a Multicenter Prospective Proof of Concept Phase II Study of the French Oculo-Cerebral Lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)*. Ann Oncol. 2019, 30 : 621-628
- Gruel Y, Rollin J. *Fibronectin: a double hit modulator in HIT?* Blood. 2019,133 : 891-892
- Gruel Y, Kizlik-Masson C, Lenting P. *[Therapeutic antibodies in hemostasis. From the past to the future]*. Med Sci (Paris). 2019, 35 : 1022-1025
- Ibrahim S, Dakik H, Vandier C, Chautard R, Paintaud G, Mazurier F, Lecomte T, Guéguinou M, Raoul W. *Expression Profiling of Calcium Channels and Calcium-Activated Potassium Channels in Colorectal Cancer*. Cancers (Basel). 2019 Apr 19;11(4). pii: E561.
- Jaimes-Albornoz D, Mannone L, Nguyen-Quoc S, Chalandon Y, Chevallier P, Mohty M, Meunier M, Robin M, Ledoux MP, Guillerm G, Bay JO, Poiré X, Maillard N, Leclerc M, Daguindau E, Beguin Y, Rubio MT, Gyan E.

*Allogeneic Stem Cell Transplantation in Therapy-Related Myelodysplasia after Autologous Transplantation for Lymphoma: A Retrospective Study of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy.*

Biol Blood Marrow Transplant. 2019, 25 : 2366-2374

- Kizlik-Masson C, Deveuve Q, Zhou Y, Vayne C, Thibault G, McKenzie SE, Pouplard C, Loyau S, Gruel Y, Rollin J  
*Cleavage of anti-PF4/heparin IgG by a bacterial protease and potential benefit in heparin-induced thrombocytopenia.*  
Blood. 2019, 133 : 2427-2435
- Kouzi F, Zibara K, Bourgeois J, Picou F, Gallay N, Brossaud J, Dakik H, Roux B, Hamard S, Le Nail LR, Hleihel R, Foucault A, Ravalet N, Rouleux-Bonnin F, Gouilleux F, Mazurier F, Bene MC, Akl H, Gyan E, Domenech J, El-Sabban M, Herault O.  
*Correction: Disruption of gap junctions attenuates acute myeloid leukemia chemoresistance induced by bone marrow mesenchymal stromal cells.*  
Oncogene. 2019 Nov 7. doi: 10.1038/s41388-019-1089-7. [Epub ahead of print]
- Lejeune J, Brachet G, Watier H.  
*Evolutionary Story of the Low/Medium-Affinity IgG Fc Receptor Gene Cluster.*  
Front Immunol. 2019, 10 : 1297.
- Leveque X, Hochane M, Geraldo F, Dumont S, Gratas C, Oliver L, Gaignier C, Trichet V, Layrolle P, Heymann D, Herault O, Vallette FM, Olivier C.  
*Low-Dose Pesticide Mixture Induces Accelerated Mesenchymal Stem Cell Aging In Vitro.*  
Stem Cells. 2019, 37 : 1083-1094
- Martin C, Brachet G, Colas C, Allard-Vannier E, Kizlik-Masson C, Esnault C, Respaud R, Denevault-Sabourin C, Chourpa I, Gouilleux-Gruart V, Viaud-Massuard MC, Joubert N.  
*In Vitro Characterization and Stability Profiles of Antibody-Fluorophore Conjugates Derived from Interchain Cysteine Cross-Linking or Lysine Bioconjugation.*  
Pharmaceuticals (Basel). 2019 Dec 2;12(4).
- Martineau P, Watier H, Pèlerin A, Turtoi A.  
*Targets for MAbs: innovative approaches for their discovery & validation, LabEx MAbImprove 6th antibody industrial symposium, June 25-26, 2018, Montpellier, France.*  
MAbs. 2019, 11 : 812-825
- Mease P, Roussou E, Burmester GR, Goupille P, Gottlieb A, Moriarty SR, Benichou O, Adams DH, Xu W, Nash P.  
*Safety of Ixekizumab in Patients With Psoriatic Arthritis: Results From a Pooled Analysis of Three Clinical Trials.*  
Arthritis Care Res (Hoboken). 2019, 71 : 367-378
- Neiveyans M, Melhem R, Arnoult C, Bourquard T, Jarlier M, Busson M, Laroche A, Cerutti M, Pugnières M, Ternant D, Gaborit N, Chardès T, Poupon A, Gouilleux-Gruart V, Pèlerin A, Poul MA.  
*A recycling anti-transferrin receptor-1 monoclonal antibody as an efficient therapy for erythroleukemia through target up-regulation and antibody-dependent cytotoxic effector functions.*  
MAbs. 2019, 11 : 593-605
- Nguyen TT, Angeli E, Darrouzain F, Nguyen QT, Desvignes C, Rigal M, Nevine O, Nicolas P, Le QV, Winterman S, Paillet MC, Zelek L, Paintaud G, Janin A, Bousquet G.  
*A successful compartmental approach for the treatment of breast cancer brain metastases.*  
Cancer Chemother Pharmacol. 2019, 83 : 573-580

- Paris J, Morgan M, Campos J, Spencer GJ, Shmakova A, Ivanova I, Mapperley C, Lawson H, Wotherspoon DA, Sepulveda C, Vukovic M, Allen L, Sarapuu A, Tavosanis A, Guitart AV, Villacreces A, Much C, Choe J, Azar A, van de Lagemaat LN, Vernimmen D, Nehme A, Mazurier F, Somerville TCP, Gregory RI, O'Carroll D, Kranc KR.

*Targeting the RNA m6A Reader YTHDF2 Selectively Compromises Cancer Stem Cells in Acute Myeloid Leukemia.*

Cell Stem Cell. 2019 Jul 3;25(1):137-148.e6

- Petitcollin A, Bensalem A, Verdier MC, Tron C, Lemaitre F, Paintaud G, Bellissant E, Ternant D. *Modelling of the Time-Varying Pharmacokinetics of Therapeutic Monoclonal Antibodies: A Literature Review.* Clin Pharmacokinet. 2019 Aug 26. doi: 10.1007/s40262-019-00816-7. [Epub ahead of print]

- Picou F, Vignon C, Debeissat C, Lachot S, Kosmider O, Gallay N, Foucault A, Estienne MH, Ravalet N, Bene MC, Domenech J, Gyan E, Fontenay M, Herault O.

*Bone marrow oxidative stress and specific antioxidant signatures in myelodysplastic syndromes.*

Blood Adv. 2019, 3 : 4271-4279

- Pivot X, Goupille P.

*[Biosimilars Antibodies: Positioning Compared to Originators - The Experience in Rheumatology and the Biosimilars of Trastuzumab in Oncology]*

Med Sci (Paris). 2019, 35 : 1137-1145

- Sébert M, Renneville A, Bally C, Peterlin P, Beyne-Rauzy O, Legros L, Gourin MP, Sanhes L, Wattel E, Gyan E, Park S, Stamatoullas A, Banos A, Laribi K, Jueliger S, Bevan L, Chermat F, Sapena R, Nibourel O, Chaffaut C, Chevret S, Preudhomme C, Adès L, Fenaux P.

*A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure.*

Haematologica. 2019, 104 : 1565-1571

- Susen S, Gruel Y, Godier A, Harroche A, Chambost H, Lasne D, Rauch A, Roullet S, Fontana P, Goudemand J, de Maistre E, Chamouard V, Wibaut B, Albaladejo P, Négrier C.

*Management of bleeding and invasive procedures in haemophilia A patients with inhibitor treated with emicizumab (Hemlibra®): Proposals from the French network on inherited bleeding disorders (MHEMO), the French Reference Centre on Haemophilia, in collaboration with the French Working Group on Perioperative Haemostasis (GIHP).*

Haemophilia. 2019, 25 : 731-737

- Ternant D, Monjanel H, Venel Y, Prunier-Aesch C, Arbion F, Colombat P, Paintaud G, Gyan E.

*Nonlinear pharmacokinetics of rituximab in non-Hodgkin lymphomas: a pilot study.*

Br J Clin Pharmacol. 2019, 85 : 2002-2010

- Ternant D, Chhun S.

*[Pharmacokinetic Variability of Therapeutic Antibodies]*

Med Sci (Paris). 2019, 35 : 1130-1136

- Vayne C, May MA, Bourguignon T, Lemoine E, Guery EA, Rollin J, Gruel Y, Pouplard C.

*Frequency and Clinical Impact of Platelet Factor 4-Specific Antibodies in Patients Undergoing Extracorporeal Membrane Oxygenation.* Thromb Haemost.

2019, 119 : 1138-1146